AstraZeneca

AZN

Market cap $263B

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

NEW YORK--(BUSINESS WIRE)--On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint in ATTR cardiomyopathy. If you suffered a loss on your AstraZeneca investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. Wainua, a gene-silencing drug for transthyr.

HSBC has downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', arguing that a recent trial failure has removed the central pillar of its bull case and left a tougher path ahead. The bank cut its target price to 13,750p from 16,500p, implying limited upside.

UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees little room for the drugmaker to raise full-year guidance. The bank reiterated its 'buy' rating on Britain's second most valuable listed company, ahead of results due on 27 July.

Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs.

AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years. Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was about more than a single drug.

The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of affected AZN investors.

AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.